The academicians, from Chinese Academy of Science and Chinese Academy of Engineering, regret the Chinese focus on generics and plead for innovative drug development, removing bottlenecks in drug review, fiscal and taxation policies, drug bidding etc., and the lack of competition and innovation in the Chinese drug industy.

China Bio news release, October 21, 2016